Eric Liu, MD
Internal Medicine · San Diego, CANPI 1609865377
Payments from drug & device makers
Across 90 payments — averaging $36.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Pharmaceuticals Incorporated$1K
- Histosonics, Inc.$667
- AstraZeneca$235
- Amgen$230
- GSK$214
- AbbVie$113
- plus $737 from 19 others
What the payments were for
- Travel & lodging$1,64751%
- Food & beverage$1,58949%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Pharmaceuticals Incorporated | 4 | $1,047 |
| Histosonics, Inc. | 1 | $667 |
| AstraZeneca(2 entities) | 9 | $235 |
| Amgen | 19 | $230 |
| GSK | 11 | $214 |
| AbbVie | 6 | $113 |
| Novo Nordisk | 7 | $111 |
| Pfizer | 5 | $92 |
| Novartis | 3 | $73 |
| Gilead | 3 | $66 |
| Merck | 2 | $45 |
| Exact Sciences | 2 | $40 |
| Lilly USA, LLC | 2 | $38 |
| Antares Pharma, Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $32 |
| Boston Scientific | 2 | $30 |
| Astellas Pharma US Inc | 2 | $29 |
| Medtronic | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Bayer | 1 | $19 |
| Abbott | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Duchesnay USA Incorporated | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,242 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $72,997 |
| EliquisApixaban | 29 | $38,919 |
| RybelsusSemaglutide | 13 | $25,533 |
| OzempicSemaglutide | 19 | $21,413 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $12,315 |
| XareltoRivaroxaban | 15 | $11,544 |
| Rosuvastatin Calcium | 319 | $3,887 |
| Atorvastatin Calcium | 364 | $3,513 |
| Losartan Potassium | 271 | $3,287 |
| Testosterone | 15 | $3,206 |
| SynthroidLevothyroxine Sodium | 48 | $2,988 |
| Azelastine Hcl | 84 | $2,737 |
| Ipratropium Bromide | 42 | $2,421 |
| Levothyroxine Sodium | 269 | $2,368 |
| Amlodipine Besylate | 318 | $2,243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $32 | $72,99758 claims |
| Novo NordiskRybelsus, Ozempic | $111 | $46,94632 claims |
| PfizerEliquis | $92 | $38,91929 claims |
| GSKBreo Ellipta | $214 | $12,31520 claims |
| AbbVieSynthroid | $113 | $2,98848 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Diego
- Donald BrandonSan Diego$34M
- Elaine WatkinsSan Diego$11.3M
- James ChenSan Diego$2.9M
- Rita StarrittSan Diego$2.6M
- Hatim HusainSan Diego$2.6M
- Gary FiresteinSan Diego$2.6M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.